Atilmotin (also known as BAX-ACC-1638), a motilin receptor agonist, is short acting, with t1/2 less than 10 min. It was shown that at doses of 6, 30 or 60 mg intravenously, it affected esophageal, lower esophageal sphincter (LES), and gastric motility. LES and gastric pressures were increased, whereas there was disruption of esophageal peristalsis characterized by lower amplitude and failed contractions. The drug can have the clinical implementation for stomach motility disorders but is needed further study.

Encyprate (MO-1255) is a unique drug in being inactive as an MAO inhibitor in vitro but very active in vivo. It most probably is converted by the body to ethyl-N-benzyl-N-cyclopropylcarbamate which is an active MAOI in vitro. I was studying in the treatment of depression.

Tasuldine is as an orally active bronchosecretolytic agent that was clinically effective in human. However, information about the further development and use of this drug is not available.

Tisocalcitate is the vitamin D derivative. Tisocalcitate ointment is currently in phase 2 clinical development for mild to moderate psoriasis. Early studies have shown that, unlike other vitamin D3 analogues, tisocalcitate does not affect calcium metabolism. Tisocalcitate ointments were tolerated well and were safe to use on healthy skin. Tisocalcitate had been in phase II clinical trial for the treatment of psoriasis. However, this development was discontinued.

Pelitrexol (also known as AG2037) was developed by Pfizer as a glycinamide ribonucleotide formyltransferase inhibitor. This drug was studied in phase II clinical trials in patients with metastatic non-small cell lung cancer and in patients with metastatic colorectal cancer who failed treatment. In addition, the drug participated in a phase I clinical trial in treating patients who have advanced, metastatic, or recurrent solid tumors. Information about the further development of pelitrexol is not available.

Tanogitran (also called as BIBT986) is a dual inhibitor of thrombin/factor Xa. Tanogitran participated in a clinical trial in endotoxin-induced coagulation, where was shown that tanogitran was a potent anticoagulant. In addition, the drug was studied in phase II clinical trial for the treatment of septic shock; however, information about the further development of this drug is not available.

Trospectomycin is an aminocyclitol antibiotic similar in structure to spectinomycin. The drug was originally developed by Pharmacia & Upjohn. It is a 6'-propyl analogue of spectinomycin, and lacks the aminosugars in glycosidic linkage which are thought to be responsible for the ototoxicity and nephrotoxicity associated with the aminoglycosides. The mechanism of action of trospectomycin is similar to that of its parent compound, spectinomycin: it binds to the bacterial 30S ribosome and inhibits protein synthesis. The transport mechanism for its delivery to its target site does not appear to be oxygen dependent, and this explains the in-vitro activity of trospectomycin against anaerobic organisms. Trospectomycin has activity against a broad spectrum of pathogenic organisms including Streptococcus, Haemophilus, Gardnerella, Neisseria, Peptococcus, Peptostreptococcus, Bacteroides, Mobiluncus, Chlamydia, Mycoplasma and Ureaplasma spp. Results of in-vivo testing suggest potential utility in a variety of clinical conditions including non-gonococcal urethritis, chlamydial cervicitis, gonorrhoea, pelvic inflammatory disease, pneumonia, anaerobic infections and meningitis. Trospectomycin progressed to late stage clinical trials for treatment of pelvic inflammatory disease (chlamydia) before being abandoned for commercial reasons as the third generation cephalosporins and second generation macrolides in development and use were judged superior at the time.

Cinoxolone is a derivative of glycyrrhetinic acid. Is is claimed to possess antiulcer properties.

Resorantel (HOE 296V) is an anthelmintic agent. Resorantel was found to be highly effective against Houttuynia struthionis (a tapeworm, parasite of the small intestine) in ostriches. Resorantel also showed anthelmintic efficacy against Thysaniezia giardi and Avitellina spp. (both tapeworms) when tested in sheep. Similar results have been found in goats and cattle.